Last reviewed · How we verify
NCT05839483
CXCR4 Targeted PET Imaging in APA Preoperative Localization Diagnosis
NA trial testing CXCR4 in Aldosterone-Producing Adenoma in 50 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Zhongnan Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 50 |
| Start date | 30 May 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CXCR4
Conditions studied
- Aldosterone-Producing Adenoma — all drugs for Aldosterone-Producing Adenoma →
Sponsor
Zhongnan Hospital
Who can join
Adults 18 to 70, any sex, with Aldosterone-Producing Adenoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the effectiveness of CXCR4 targeted PET imaging in preoperative localization diagnosis of primary aldosteronism (PA). Participants diagnosed with PA will be asked to be scanned by 68Ga-PentixaFor PET, and then underwent adrenal venous sampling (AVS). Then, the responsible adrenal adenoma will be resected by adrenalectomy, and examined with pathological section and staining. Researchers will compare the sensitivity and specificity between 68Ga-PentixaFor PET imaging and AVS in preoperative localization diagnosis of PA.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05839483
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CXCR4
Trials testing the same drug.
- NCT06234319 — CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma · unknown
- NCT06183554 — CXCR4 Targeted PET Imaging in the Diagnosis and Identification of Primary Aldosteronism · unknown
Other recruiting trials for Aldosterone-Producing Adenoma
Currently open trials in the same condition.
- NCT07027254 — PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism · NA · recruiting
- NCT05368090 — Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism · NA · recruiting
Other Zhongnan Hospital trials
Trials by the same sponsor.
- NCT07515963 — FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. · Phase 2 · not yet recruiting
- NCT07420036 — An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, · EARLY_PHASE1 · not yet recruiting
- NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
- NCT07363330 — A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07460258 — A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05839483 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongnan Hospital
- Last refreshed: 17 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05839483.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing